What is claimed:

1. Use of an oral dosage form of milvexian, or pharmaceutically acceptable salt thereof, for manufacture of a medicament for treating or preventing a venous thromboembolic disorder, wherein a total daily dose of from 25 mg to 400 mg of milvexian, or pharmaceutically acceptable salt thereof is to be orally administered to a patient in need thereof.

2. The use according to claim 1, wherein the total daily dose is from 50 mg to 400 mg.

3. The use according to claim 1, wherein the total daily dose is 25 mg.

4. The use according to claim 1, wherein the total daily dose is 50 mg.

5. The use according to claim 1, wherein the total daily dose is 100 mg.

6. The use according to claim 1, wherein the total daily dose is 150 mg.

7. The use according to claim 1, wherein the total daily dose is 200 mg.

8. The use according to any one of claims 1 to 7, wherein the total daily dose is to be administered in a single dose.

9. The use according to any one of claims 1 to 7, wherein the total daily dose is to be administered in divided doses.

10. The use according to claim 9, wherein the total daily dose is to be administered in two doses.

11. The use according to any one of claims 1 to 7, wherein the venous thromboembolic disorder is proximal and/or distal deep vein thrombosis, nonfatal pulmonary embolism, or death.

12. The use according to claim 11, wherein the venous thromboembolic disorder is proximal and/or distal deep vein thrombosis.

13. The use according to claim 11, wherein the venous thromboembolic disorder is nonfatal pulmonary embolism.

14. The use according to claim 11, wherein the venous thromboembolic disorder is death.

15. Use of an oral dosage form of milvexian, or pharmaceutically acceptable salt thereof, for manufacture of a medicament for preventing post-operative venous thromboembolism events in a patient recovering from surgery, wherein administration of said medicament to said patient results in the patient experiencing fewer post-operative venous thromboembolism events than would result from subcutaneous administration to the patient of 40 mg per day of enoxaparin.

16. The use according to claim 15, wherein the patient is recovering from abdominal surgery, knee replacement surgery, or hip replacement surgery.

17. The use according to claim 15 or claim 16, wherein the daily dose of milvexian, or pharmaceutically acceptable salt thereof, is 50 mg.

18. The use according to claim 15 or claim 16, wherein the daily dose of milvexian, or pharmaceutically acceptable salt thereof, is 100 mg.

19. The use according to claim 15 or claim 16, wherein the daily dose of milvexian, or pharmaceutically acceptable salt thereof, is 150 mg.

20. The use according to claim 15 or claim 16, wherein the daily dose of milvexian, or pharmaceutically acceptable salt thereof, is 200 mg.

21. The use according to any one of claims 15 to 16, wherein the daily dose of milvexian, or pharmaceutically acceptable salt thereof, is to be administered in a single dose.

22. The use according to any one of claims 15 to 16, wherein the daily dose of milvexian, or pharmaceutically acceptable salt thereof, is to be administered in divided doses.

23. Use of a solid dosage form of milvexian, or pharmaceutically acceptable salt thereof, for manufacture of a medicament adapted for once or twice daily administration to a patient for treating or preventing a venous thromboembolic disorder wherein said administration results in an incidence rate of total venous thromboembolism events in the patient that is less than 25% with an alpha of 5%.

24. The use of claim 23, wherein the incidence rate of total venous thromboembolism events is less than 20 %.

25. The use of claim 23, wherein the incidence rate of total venous thromboembolism events is less than 15%.

26. The use of claim 23, wherein the incidence rate of total venous thromboembolism events is less than 10%.

27. The use of claim 23, wherein the milvexian, or pharmaceutically acceptable salt thereof is to be administered at a total daily dose ranging from 50 mg to 400 mg.

28. The use of claim 23, wherein the milvexian, or pharmaceutically acceptable salt thereof is to be administered at the total daily dose selected from the group consisting of 50 mg, 100 mg, 200 mg, and 400 mg.

29. The use of claim 23, wherein the milvexian, or pharmaceutically acceptable salt thereof is to be administered at the total daily dose of 50 mg.

30. The use of claim 23, wherein the milvexian, or pharmaceutically acceptable salt thereof is to be administered at the total daily dose of 100 mg.

31. The use of claim 23, wherein the milvexian, or pharmaceutically acceptable salt thereof is to be administered at the total daily dose of 150 mg.

32. The use of claim 23, wherein the milvexian, or pharmaceutically acceptable salt thereof is to be administered at the total daily dose of 200 mg.

33. The use of claim 23, wherein the milvexian, or pharmaceutically acceptable salt thereof is to be administered at the total daily dose of 400 mg.

34. The use of any one of claims 23 to 33, wherein milvexian is to be administered twice daily.

35. The use of any one of claims 23 to 33, wherein milvexian is to be administered once daily.

36. The use of any one of claims 23 to 33, wherein the rate of venous thromboembolism occurs in a dose dependent manner without increasing the risk of bleeding compared with enoxaparin.

37. The use of any one of claims 23 to 33, wherein the therapeutically effective amount is clinically proven effective in achieving less than 25 % of the incidence rate of total venous thromboembolism events in the patient treated with milvexian, or pharmaceutically acceptable salt thereof.